"Cityslicker, at the AGM in the Q&A Don specifically said that the request for extending the embargo until "the end of March" was with respect to the renal data."

Thanks Fouremm. And yesterday, DM indicated that CTAD is the last embargo....implying no other embargoes after CTAD. So sounds like eGFR change CKD-subgroup data IS NOT under embargo. And if it is, it is part of the CTAD embargo.

From imtesty's transcript of yesterday's webcast:

"Now, new findings. On [slide] 40, we’re also going to talk just a bit about the CTAD conference coming up. This is Clinical Trials for Alzheimer ’s disease, is what CTAD stands for. And we haven’t talked and we won’t talk much about our cognitive function data until December 5th when this is presented, for the same reason we haven’t been able to talk until this weekend about our true exciting data, because of embargoes for academic purposes. You will be very pleased to know these are the last two. We do not have future embargoes coming up. So in the CTAD conference in San Diego we will be participating in this session, and showing a lot of the data involved in our cognitive function. And I think you’ll find it quite exciting. Again, after this conference, we will do a webcast and update the market as well."

BDAZ